HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
about
Targeted drugs in small-cell lung cancerHSP90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivoNuclear heat shock protein 110 expression is associated with poor prognosis and chemotherapy resistance in gastric cancer.Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: a potential antagonistic role for p21.Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activationDalbergioidin Ameliorates Doxorubicin-Induced Renal Fibrosis by Suppressing the TGF-β Signal PathwayThe Expression of HSPD1, SCUBE3, CXCL14 and Its Relations with the Prognosis in Osteosarcoma.Ganetespib for small cell lung cancer.Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer.miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells.Synthesis and biological evaluation of geldanamycin analogs against human cancer cells.An inducible heat shock protein 70 small molecule inhibitor demonstrates anti-dengue virus activity, validating Hsp70 as a host antiviral target.Ganetespib induces G2/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling.A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.Targeting chaperonin containing TCP1 (CCT) as a molecular therapeutic for small cell lung cancer.Nuclear heat shock protein 110 expression is associated with poor prognosis and hyperthermo-chemotherapy resistance in gastric cancer patients with peritoneal metastasis.Identification of Hsp90 inhibitors with anti-Plasmodium activity.HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.Advanced small cell lung cancer (SCLC): new challenges and new expectations.A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer.
P2860
Q26767017-5816DB4F-6346-4696-ADA5-8C20C5D22881Q27320833-E16016E0-8892-45E1-B1A4-5004E5C716FDQ27853356-041BA0D3-8C42-467A-AB0E-0EB4360C62E5Q35484306-F8D8DAD2-2219-440E-9843-DF4A70F122CEQ35602561-6685EFBA-ED2A-4759-AC60-F2E2CB8E7365Q35833001-439DF399-0955-40E7-B2AA-B1AF7AF959D3Q37558117-883E2220-323E-453A-98DB-7B8D6301B227Q38766777-D9AC16FC-C379-4E63-B84C-4DA05B8C60E5Q38786678-506E0C86-07C8-4579-9FAE-2370233CE4DDQ38834735-8F85FAA9-A528-4AF9-8B4E-068326DE1D4DQ38905678-C23891A5-81C7-4EF7-8DA7-FB2EC3FDECBEQ38909847-62A24438-A5E2-4C60-86F6-5CDFC3115046Q40110604-FD86EDC5-D41F-4A6E-B844-D5C33FC8667BQ41470003-4F164039-AEB0-4BCD-A637-DBE950307CAAQ42382771-196AAE06-BF2B-4E64-BABA-75EFB4FDB505Q47107751-088A56FF-D882-4B1D-A94F-C50EA93FDEE0Q47285124-BD8B15AE-37A5-45C5-8485-1F61A0CA7632Q48022253-815146C8-9E11-489B-9A55-8F1004D5DB2AQ48292976-E1C6A65E-74E9-4DFA-8710-499F081F6A61Q52714930-A93B38B4-DFFE-4798-947F-5159B11C6D45Q54977232-566AC9D0-44A9-4360-A478-17F217480A00Q55081754-8DAEAE85-5DD0-46A1-9942-059E2F0E6996
P2860
HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
@en
HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
@nl
type
label
HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
@en
HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
@nl
prefLabel
HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
@en
HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
@nl
P2093
P2860
P356
P1433
P1476
HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer
@en
P2093
A T Alberobello
E F Petricoin Iii
M Pierobon
P2860
P2888
P304
P356
10.1038/ONC.2013.439
P407
P577
2013-10-28T00:00:00Z